{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T02:17:03Z","timestamp":1784945823266,"version":"3.55.0"},"reference-count":39,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,12,13]],"date-time":"2012-12-13T00:00:00Z","timestamp":1355356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Ophthalmologica"],"published-print":{"date-parts":[[2013,2]]},"abstract":"<jats:title>Abstract.<\/jats:title><jats:p><jats:bold>Purpose:\u2002<\/jats:bold> To assess the effect of SofZia\u2010preserved travoprost on ocular surface conditions in comparison with benzalkonium chloride (BAK)\u2010preserved latanoprost.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> A prospective randomized multicentre single\u2010masked comparative study. Patients with open\u2010angle glaucoma or ocular hypertension who had been treated with BAK\u2010preserved latanoprost 0.005% (Xalatan<jats:sup>\u00ae<\/jats:sup>) monotherapy for at least 3\u2003months. Patients were enrolled at 23 facilities. Patients were randomly divided into the X\u2010X group, continuous use of Xalatan<jats:sup>\u00ae<\/jats:sup>, or the X\u2010T group, switching from Xalatan<jats:sup>\u00ae<\/jats:sup> to SofZia\u2010preserved travoprost 0.004% (TravatanZ<jats:sup>\u00ae<\/jats:sup>), and followed for 3\u2003months. The superficial punctate keratopathy (SPK), conjunctival epitheliopathy, hyperaemia, tear break\u2010up time (TBUT) and intraocular pressure (IOP) were examined for each patient in a masked manner. Changes in the frequency of keratoconjunctival epitheliopathy were evaluated 3\u2003months after study initiation. Intra\u2010 and intergroup comparisons of changes in SPK, conjunctival epitheliopathy, hyperaemia, TBUT and IOP were also carried out.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Two hundred twenty patients participated and 215 completed the 3\u2010month study. The frequency of keratoconjunctival epitheliopathy significantly decreased in the X\u2010T group (p\u2003=\u20030.036) and the intergroup difference was also significant (p\u2003=\u20030.001). SPK scores and TBUT were significantly improved in the X\u2010T group (p\u2003=\u20030.034, 0.049), also with significant intergroup differences in the cornea excluding the inferior area and TBUT. There were no significant intergroup differences in changes of the hyperaemia scores and the IOP reduction.<\/jats:p><jats:p><jats:bold>Conclusion:\u2002<\/jats:bold> Switching to SofZia\u2010preserved travoprost after BAK\u2010preserved latanoprost resulted in a lower incidence of keratoconjunctival epitheliopathy, especially in the cornea, with no clinically relevant changes in hyperaemia and IOP.<\/jats:p>","DOI":"10.1111\/j.1755-3768.2012.02565.x","type":"journal-article","created":{"date-parts":[[2012,12,14]],"date-time":"2012-12-14T05:07:20Z","timestamp":1355461640000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Effects of SofZia\u2010preserved travoprost and benzalkonium chloride\u2010preserved latanoprost on the ocular surface \u2013 a multicentre randomized single\u2010masked study"],"prefix":"10.1111","volume":"91","author":[{"given":"Makoto","family":"Aihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Oshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Araie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the EXTraKT study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,12,13]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0b013e3181fc8129"},{"key":"e_1_2_6_3_1","first-page":"1806","article-title":"Effects of benzalkonium chloride\u2010 or polyquad\u2010preserved fixed combination glaucoma medications on human trabecular meshwork cells","volume":"17","author":"Ammar DA","year":"2011","journal-title":"Mol Vis"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0b013e3181666557"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2009.01731.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.07-0266"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/02713680801971857"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.3109\/02713683.2011.578781"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2010.0111"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/0039-6257(80)90072-7"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6702873"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-9071.2004.00782.x"},{"key":"e_1_2_6_13_1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1076\/0271-3683(200002)2021-DFT085","article-title":"Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cells","volume":"20","author":"De Saint Jean M","year":"2000","journal-title":"Curr Eye Res"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.5301\/ejo.5000001"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0b013e31815a3472"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.04-1331"},{"key":"e_1_2_6_17_1","first-page":"613","article-title":"Efficacy, safety, and improved tolerability of travoprost BAK\u2010free ophthalmic solution compared with prior prostaglandin therapy","volume":"2","author":"Henry JC","year":"2008","journal-title":"Clin Ophthalmol"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/00061198-200406000-00004"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2007.135111"},{"key":"e_1_2_6_20_1","first-page":"291","article-title":"Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients","volume":"3","author":"Horsley MB","year":"2009","journal-title":"Clin Ophthalmol"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/112067210701700311"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2010.0003"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e31815cf651"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/15569520902995834"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0b013e318050ab7a"},{"key":"e_1_2_6_26_1","first-page":"221","article-title":"Report of the National Eye Institute\/Industry workshop on clinical trials in dry eyes","volume":"21","author":"Lemp MA","year":"1995","journal-title":"CLAO J"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0b013e31815c5f4f"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ijg.0000212274.50229.c6"},{"key":"e_1_2_6_29_1","first-page":"1690","article-title":"Comparison of the ocular tolerability of a latanoprost cationic emulsion versus conventional formulations of prostaglandins: an in vivo toxicity assay","volume":"15","author":"Liang H","year":"2009","journal-title":"Mol Vis"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.86.4.418"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2415-11-8"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2011.02338.x"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(02)01980-3"},{"key":"e_1_2_6_34_1","unstructured":"TravatanZ interview form. Available at:http:\/\/www.alcon.co.jp\/hcp\/pharmaceutical\/pdf\/1_3_Travatanz_Interviewform_200811.pdf(accessed on 13 January 2009)."},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2008.01380.x"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2005.01.042"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2009.0134"},{"key":"e_1_2_6_38_1","unstructured":"Xalatan interview form. Available at:http:\/\/products.pfizer.co.jp\/documents\/if\/xal\/xal01if.pdf(accessed on 13 January 2009)."},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-009-0754-8"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02850039"}],"container-title":["Acta Ophthalmologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1755-3768.2012.02565.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1755-3768.2012.02565.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T06:06:17Z","timestamp":1698645977000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1755-3768.2012.02565.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,13]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["10.1111\/j.1755-3768.2012.02565.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1755-3768.2012.02565.x","archive":["Portico"],"relation":{},"ISSN":["1755-375X","1755-3768"],"issn-type":[{"value":"1755-375X","type":"print"},{"value":"1755-3768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,13]]},"assertion":[{"value":"2012-12-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}